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Background: Fibroblast growth factor 23 (FGF-23) is a phosphorus-regulating hormone. In
chronic kidney disease (CKD), circulating FGF-23 levels are markedly elevated and indepen-
dently associated with mortality. Left ventricular hypertrophy (LVH) is a potent risk factor
for mortality in CKD, and FGFs have been implicated in the pathogenesis of myocardial
hypertrophy. In addition, the effect of anemia on CV disease and LVH is well known in CKD.
A relation between iron and FGF-23 metabolism is mentioned in a few studies. The aim of
this study was to test the association of FGF-23 levels with echocardiographic (ECHO) and
iron parameters in peritoneal dialysis patients (PD).
Methods: In this cross-sectional study, 61 subjects with PD (29 women and 32 men, mean
age: 46.9±13.3 years, mean PD vintage: 69.5±39 months) underwent echocardiograms to
assess left ventricular mass index (LVMI). Medical treatments and average values of the
basic laboratory results of the last 6 months for all patients were recorded. Serum FGF-
23 concentrations were measured using intact FGF-23 (iFGF-23) human enzyme-linked
immunosorbent assay (ELI˙SA) kit. According to the median levels of serum FGF-23 the
patients were grouped into two (FGF-23 high and low groups).
Results: Signiﬁcant positive correlation was recorded between serum FGF-23 levels and
LVMI (P=0.023). There was also signiﬁcant difference in terms of hemoglobin (12.1±2 ver-
sus 11.0±2, P=0.017), transferrin saturation (TSAT) (24.9±16.8 versus 19.5±10.8, P=0.042)
between low and high FGF-23 group. Also in linear regression analysis the negative relation
between FGF-23 and hemoglobin is persisted (r=0.199, P=0.045).
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Conclusions: FGF-23 is associated with LVMI, anemia and low TSAT in patients with PD.
Whether increased FGF-23 is a marker or a potential mechanism of myocardial hypertrophy
and anemia in patients with end-stage renal disease (ESRD) requires further study.
© 2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
El factor de crecimiento ﬁbroblástico está asociado con el índice de masa
ventricular izquierda, anemia y niveles bajos de saturación de la
transferrina
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Introducción: El factor de crecimiento ﬁbroblástico 23 (FGF-23) es una hormona reguladora
del fósforo. En la enfermedad renal crónica (ERC), los niveles de FGF-23 son especialmente
elevados y se relacionandemanera independiente conmortalidad. Lahipertroﬁa ventricular
izquierda (HVI) es un importante factor de riesgo de mortalidad en la ERC y se ha implicado
a los FGF en la patogenia de la hipertroﬁa del miocardio. Además, se conoce el efecto de la
anemia en la enfermedad cardiovascular y laHVI en la ERC. En algunos estudios semenciona
una relación entre el hierro y el metabolismo del FGF-23. El objetivo de este estudio fue
comprobar la asociación de los niveles de FGF-23 con parámetros ecocardiográﬁcos y de
hierro en pacientes con diálisis peritoneal (DP).
Metodología: En este estudio transversal se procedió a realizar un ecocardiograma a 61indi-
viduos con DP (29 mujeres y 32 hombres; media de edad: 46,9±13,3 an˜os; DP clásica media:
69,5±39 meses) para evaluar el índice de masa ventricular izquierda (IMVI). Se registraron
los tratamientos médicos y los valores promedio de los resultados básicos de laboratorio
de los últimos 6 meses de todos los pacientes. Las concentraciones en suero del FGF-23 se
midieron con el kit ELISA (enzyme-linked immunosorbent assay) de FGF-23 humano intacto
(iFGF-23). Según los niveles promedio de FGF-23 en suero, los pacientes se distribuyeron en
dos grupos (FGF-23 alto y bajo).
Resultados: Se registró una correlación positiva signiﬁcativa entre los niveles de FGF-23 en
suero e IMVI (P = 0,023). También hubo diferencias signiﬁcativas en cuanto a la hemoglobina
(12,1±2 frente a 11,0±2, P = 0,017) y saturación de la transferrina (TSAT; 24,9±16,8 frente
a 19,5±10,8, P = 0,042) entre los grupos de FGF-23 bajo y alto. También en el análisis de
regresión lineal se mantuvo la relación negativa entre el FGF-23 y la hemoglobina (r = 0,199,
P = 0,045).
Conclusiones: El FGF-23 se asocia con IMVI, anemia yTSATbaja enpacientes conDP. Saber si el
aumento del FGF-23 es un marcador o un mecanismo potencial de la hipertroﬁa miocárdica
y la anemia en pacientes con insuﬁciencia renal terminal exige un estudio en mayor detalle.
© 2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-ND
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Cardiovascular disease (CVD) is the most common cause of
mortality in patients with end stage renal disease (ESRD)1.
Besides the well-known traditional cardiovascular risk fac-
tors, this population has risk factors speciﬁc to chronic kidney
disease which results in accelerated atherosclerosis2. LVH,
commonly exists in patients with ESRD, is a major cardiovas-
cular risk factor and independent predictor of cardiovascular
mortality in this population3.
Hypertension is accepted as the main underlying factor
in the development of LVH. However recent studies indi-
cated that FGF-23 may contribute to left ventricular mass
enlargement4,5. FGF-23 is phosphorus regulating hormone
and signiﬁcantly increased in patients with ESRD. It pro-
motes phosphate excretion and reduces 1-25(OH)2 vitamin
D production in the kidney6. Independent relation between
increased FGF-23 levels and mortality was ﬁrst reported by
Guirez et al.7 in 2008 in hemodialysis (HD) patients. Even in
patientswith normal renal functions higher FGF-23was found
to be independently associated with mortality and cardiovas-
cular events8. In addition, the effect of anemia on CV disease
and LVH is well known in CKD patients9. A relation between
iron and FGF-23 metabolism is mentioned in a few studies. In
studies, it is emphasized that iron deﬁciency is an important
stimulator of FGF-23 transcription10. The aim of this cross-
sectional study was to investigate the possible relationship
between serum levels of FGF-23 with ECHO and iron parame-
ters in PD patients.
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Materials and methods
Subjects
This study was performed in peritoneal dialysis patients that
are regularly followed in Ankara Diskapi Yildirim Beyazit
Training and Research Hospital. Patients that suffered peri-
tonitis or acute coronary event within last 2 months and
patients with active malignancy were excluded. Sixty-one
patients were included in the study. Fifty-one patients were
on continuous ambulatory peritoneal dialysis program and
10 on automated peritoneal dialysis program. In all patients,
the doses of dialysis were prescribed so as to generate a Kt/V
of >1.7. Demographic characteristics, co-morbidities, medical
treatments and average values of the basic laboratory results
of the last 6 months for all patients were recorded. Residual
renal function was expressed as the mean value of the resid-
ual urea and creatinine clearances. Peritoneal equilibration
test (PET) was applied according to the method described by
Twardowski et al.11.
FGF-23 measurements
In all patients, 5ml of blood samples were obtained from
peripheral vein after an overnight fasting into standard tubes
biochemistry between 08.00 and 12.00AM. Within 30min of
collection, samples were centrifuged at 2000 rpm for 10min
and stored in −80 ◦C for maximum 1 month. Serum FGF-23
concentrationsweremeasured using human iFGF-23 ELISA kit
(Uscn Life Science Inc., Wuhan, China) which has typically a
sensitivity of less than 4pg/ml.
Echocardiography
All ECHO measurements were made according to the recom-
mendations of the American Society of Echocardiography12.
Patients were evaluated in semi-supine position in a dark
room by the same cardiologist who was unaware of the clini-
cal and laboratory data of the patients. Ejection fraction (EF),
left ventricular end-systolic diameter (LVESD), left ventricular
end-diastolic diameter (LVEDD), left ventricular posterior wall
thickness (PWT), inter-ventricular wall thickness (IVWT) and
left ventricular relaxation was evaluated in parasternal plane
according to the guideline. The LVMI was calculated with the
Devereux formula13. Body surface area was calculated with
the formula of DuBois and DuBois14. Cut-off values for LVH
were deﬁned as 131g/m2 and 100g/m2 for men and women
by considering the measurements in the Framingham Heart
Study15,16.
Ethics
This study was approved by the local ethics committee of
Ankara Diskapi Yildirim Beyazit Training and Research Hospi-
tal. The study was conducted in accordance with Declaration
of Helsinki and all participants provided written informed
consents.
Table 1 – Properties of patients.
n=61
Age (year) 46.9±13.3
Sex women (n, %) 29 (%47.5)
Body mass index (kg/m2) 25.4±3.8
Dialysis vintage (months) 69.5±39.7
SAPD/APD (%) 84/16
Systolic blood pressure (mmHg) 129±20
Diastolic blood pressure (mmHg) 81±11
Mean arterial pressure (mmHg) 98±18
Causes of ESRD (n, %)
Hypertension 14 (23)
Chronic glomerulonephritis 11 (18)
Diabetes 6 (9.8)
Others 7 (11.5)
Unknown 23 (37.7)
Concomitant disease (n, %)
Hypertension 37 (60.7)
Hyperlipidemia 19 (31.2)
Diabetes 7 (11.5)
Coronary artery disease 4 (6.6)
Cerebrovascular event 2 (3.3)
Smoking (n, %) 13 (21.3)
SAPD/APD, sustained ambulatory peritoneal dialysis/instrumental
peritoneal dialysis; ESRD, end stage renal disease.
Statistical analysis
Data analysis was performed by using “SPSS for Windows
19” (SPSS Inc., Chicago, USA). Results of the analysis of con-
tinuous variables were expressed as mean±SD and median
[min–max] while the results of analysis of discrete variables
were expressed as frequency distributions and percentages.
Median serum FGF-23 value was used as the cut-off point and
low-and high-FGF-23 groups were formed. In FGF-23 groups,
demographic, clinical and laboratory data were compared
pairwise. The Kolmogorov–Smirnov test was used for testing
normality of continuous variables. Normally distributed vari-
ables were analyzed by t-test while others were analyzed with
the Mann–Whitney U test. Chi-square test was used for com-
parison of discrete variables. Linear regression analysis model
was used to study the relationship between LVMI and FGF-23.
P<0.05 was considered statistically signiﬁcant.
Results
There were 61 PD patients (32 men and 29 women, mean
age 46.9±13.3 years) that fulﬁll the inclusion and exclusion
criteria. Demographic characteristics, co-morbidities, medi-
cal treatments and basic laboratory results of the patients
are presented in Tables 1 and 2. The average LVMI of the
patients was 140±48g/m2 and LVH was present in 69% of
patients according to the criteria presented in ‘Methods’
section. This prevalence was consistent with the previous
studies17,18. Although the average EF of patientswas 60.2±6%,
left ventricular relaxation dysfunction (LVRD) was observed
in majority of the patients (48 patients, 77%) (Table 4). Mean
serum FGF-23 level was determined to be 26.3±8.3pg/ml
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Table 2 – Treatment properties of patients.
n=61
Anti-hypertensive (n, %)
CCB 26 (42.6)
RAS blocker 17 (27.9)
ˇ-Blocker 16 (26.2)
˛-Blocker 9 (14.8)
Antihyperlipidemics (%)
Statins 10 (16.4)
Gemﬁbrozil 7 (11.5)
Active vitamin D (%) 40 (65.6)
P binders (%)
Ca-acetate 45 (73.7)
Sevelamere-HCl 8 (13.1)
No. of P binders 5 (8.2)
Oral iron (%) 42 (68.9)
Erythropoietin (%) 34 (55.7)
Erythropoietin dosage (u/week) 8000±2500
CCB, calcium channel blockers; RAS, renin angiotensin system.
[median 23.5pg/ml (min–max; 11.53–45.63)] (Table 3) and
this value was similar to the values observed in previous
studies19. Median value of FGF-23 (23.5 pg/ml) was taken as
a cut-off point and patients were divided into the low-and
high-FGF-23 groups. Demographic, somatometric, laboratory
and ECHO results of the two groups were compared (Table 5).
No statistically signiﬁcant difference was observed between
the two groups with regard to age, gender, duration of
dialysis, BMI, waist circumference, presence of co-morbid
diseases, smoking, and medical treatments. There were sta-
tistically signiﬁcant differences in systolic blood pressure
(SBP) and mean blood pressure (MBP) between low and high
FGF-23 groups (134.8±20.5 versus 126.3±16.5mmHg; P=0.04
Table 3 – Laboratory ﬁndings of patients.
Parameters n=61
Hemoglobin (g/dl) 11.5±2
Hemoglobin<10g/dl (n, %) 14 (23)
Transferrin saturation (%) 22±14
Ferritin (ng/ml) 296±375
Glucose (mg/dl) 104±22
Serum creatinine (mg/dl) 9.6±1.1
Serum albumin (g/dl) 3.8±0.4
C-reactive protein (mg/dl) 1.5±2.1
Alkaline phosphatase (U/L) 127±88
Calcium (Ca) (mg/dl) 9.2±0.7
Phosphorus (P) (mg/dl) 5.0±1.3
Ca×P product (mg2/dl2) 47±12
Intact parathormone (pg/ml) 481±328
Total cholesterol (mg/dl) 188±45
Triglyceride (mg/dl) 176±106
LDL-Chol (mg/dl) 112±35
HDL-Chol (mg/dl) 40±13
Kt/V 2.1±0.5
Cre Cl (L/week/1.73m2) 65.7±21
RRF≥100ml/day (n, %) 21 (34.4)
MIS* 4.1±1.9
FGF-23 (pg/ml) 26.3±8.3
Table 4 – Echocardiographic ﬁndings of patients.
Parameters n=61
Septal thickness (cm) 1.1±0.2
PDT (cm)a 1.1±0.2
LVEDD (cm)a 4.8±0.6
LVESD (cm)a 3.1±0.5
EF (%)a 60.2±6
LVMI (g/m2)a 140±48
LVH (n, %)a 42 (69)
LVDD (n, %)a 48 (77)
a LVEDD; left ventricular end-diastolic diameter, LVESD; left
ventricular end-systolic diameter, EF; ejection fraction, LVMI;
left ventricular mass index; LVH; left ventricular hypertrophy,
LVDD; left ventricular diastolic disfunction, PDT; posterior wall
thickness.
and 96.3±17.6 versus 103±17.6mmHg; P=0.04 respectively).
However no statistically signiﬁcant difference was observed
for DBP (73.8±10.9 versus 83.3±11.7, P=0.157). There was
also signiﬁcant difference in terms of hemoglobin (12.1±2
versus 11.0±2, P=0.017), TSAT (24.9±16.8 versus 19.5±10.8,
P=0.042), albumin-corrected serum calcium (9.4±0.6 versus
9.0±0.7, P=0.006), andKt/V (2.2±0.5 versus 2.0±0.4, P=0.029)
between low and high FGF-23 groups.
The parameters that were statistically signiﬁcantly differ-
ent between two groups were included in by multiple linear
regression models to determine the effect of independent
variables on FGF-23. As a result of analysis, signiﬁcant neg-
ative relationship of serum calcium (r=0.057, P=0.046) and
hemoglobin (r=0.199, P=0.045) was sustained (Table 6). Dis-
tribution graphics of statistical relation between FGF-23 and
hemoglobin concentration were shown in Fig. 1.
The results of ECHO parameters were compared in two
groups and LVMI was found to be statistically signiﬁcantly
higher in high FGF-23 group (128±35 versus 150±39g/m2,
P=0.023) but prevalence of LVH was not statistically different
between the groups (58% versus 80%, P=0.116). There were
also no differences with regard to other ECHO parameters
17.50
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Fig. 1 – Distribution graph of relation between FGF-23 and
Hgb (r=0.199, P=0.045).
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Table 5 – Laboratory and echocardiographic ﬁndings in respect to FGF-23.
Parameters FGF-23≤23.5pg/ml
n=31
FGF-23>23.5pg/ml
n=30
P
Hemoglobin (g/dl) 12.1±2 11.0±2 0.017
Transferrin saturation (%) 24.9±16.8 19.5±10.8 0.042
Ferritin (ng/ml) 229±199 384±516 0.279
Glucose (mg/dl) 107.3±27.2 99.5±14.7 0.094
Serum creatinine (mg/dl) 9.5±1.9 9.7±2 0.608
Serum albumin (g/dl) 3.8±0.4 3.7±0.5 0.371
C-reactive protein (mg/dl) 1.6±2.4 1.5±1.9 0.665
Alkaline phosphatase (U/L) 128±71 132±109 0.583
Calcium (Ca) (mg/dl) 9.4±0.6 9.0±0.7 0.006
Phosphorus (P) (mg/dl) 4.9±1.2 5.2±1.5 0.374
Ca×P product (mg2/dl2) 46±12 47±14 0.900
Intact parathormone (pg/ml) 480±328 500±349 0.863
Total cholesterol (mg/dl) 194±49 182±42 0.329
Triglyceride (mg/dl) 176±104 188±110 0.846
LDL-C (mg/dl) 120±37 104±32 0.072
HDL-C (mg/dl) 37±11 41±13 0.199
Kt/V 2.2±0.5 2.0±0.4 0.029
CreCl (L/week/1.73m2) 67.6±22.6 65.1±19.3 0.697
RRF≥100 cc (%)* 38.7 30.0 0.655
MIS 3.9±1.8 4.1±2 0.395
LVMI (g/m2) 128±35 150±39 0.023
LVH (%)* 58 80 0.116
EF (%) 61.0±3.4 58.9±9 0.661
LVDD (%)* 76.7 80 1.0
LVESD (cm) 3.0±0.3 3.2±0.6 0.510
CreCl, creatinine clearance; EF, ejection fraction; HDL-C, high-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; LVDD, left ven-
tricular diastolic disfunction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; LVH, left ventricular
hypertrophy; LVMI, left ventricular mass index; MIS, malnutrition inﬂammation score; PDT, posterior wall thickness; RRF, renal residual fraction.
Table 6 – Logistic regression analysis of factors
associated with FGF-23.
Parameters ˇ Standard
deviation
P
Systolic blood pressure 0.027 0.025 0.290
Mean arterial pressure −0.014 0.028 0.612
Hemoglobin −0.316 0.158 0.045*
Transferrin saturation −0.045 0.029 0.118
Calcium −1.074 0.539 0.046*
Kt/V −0.796 0.789 0.313
∗ P<0.05.
between two groups. Linear regression analysis was applied
to investigate the effect of the serum levels of FGF-23 on LVMI
and the relationship was found to be statistically signiﬁcant
(r=0.290, P=0.024) (Table 7). The distribution graph of the rela-
tionship between LVMI and FGF-23 can be seen in Fig. 2.
Table 7 – Simple linear regression analysis of left
ventricular mass index with FGF-23.
Left ventricular mass index
ˇ Standard error P
FGF-23 1.339 0.576 0.024
r=0.290, F=5.397, t=2.323.
FGF-23 (pg/ml)
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Fig. 2 – Distribution graph of relationship between LVMI
and FGF-23 (r=0.290, P=0.024).
Discussion
In this study, serum levels of FGF-23 were found to be pos-
itively correlated with LVMI. This correlation is likely to be
caused by the effects of FGF-23 on left ventricular mass and
function, independent from serum calcium, phosphorus, and
parathormone levels.
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Increased FGF-23 level was shown to be associated with
LVMI and LVH in stage II–IV CKD (4.19) and chronic HD
patients20,21. Increased FGF-23 level has also been suggested
to be a mortality predictor in HD patients3,22, and this situ-
ation was thought to be associated with LVMI23. In a study
investigating the relationship between FGF-23 levels and LVH
in 62 PD patients and 30 healthy controls, serum FGF-23 levels
were found to be signiﬁcantly higher in PD patients compared
to control subjects and also in PD patients with LVH compared
to PD patients without LVH. FGF-23 levels were also positively
correlated with LVMI24. In our study we observed similar asso-
ciation between FGF-23 and LVH in PD patients. There was no
difference in other ECHO parameters between patients in high
and low FGF-23 groups.
Although observational data supports the possible rela-
tionship between the FGF-23 and CVD and CV mortality,
insufﬁcient evidence exist about the exact cause of this associ-
ation. There is not enough data about the physiological effect
of FGF-23 in extra-kidney tissue. FGF-23 receptors exist in CV
system and other tissues without klotho co-receptor25. This
condition, has led to speculation that elevated FGF-23 level
observed in progressive renal disease has no direct effect on
these tissues but recent data suggests the direct effect of FGF-
23 on the CV system26. In a recent experimental study, FGF-23
was shown to cause pathological hypertrophy in rat cardiomy-
ocytes by “calcineurin-nuclear factor of activated T cells”
without klotho and treatment with FGF-blockers reduced LVH
in experimental models of chronic renal failure27. LVH caused
by FGF-23 independent from klotho is explained by two mech-
anisms. First, longstanding high-FGF-23 level as in CRF, may
cause the attachment of FGF to FGF-23 receptor. Although this
attachment has lower afﬁnity, exposure of the heart tissue
to FGF-23, may be enough for the development of LVH. In
CKD klotho expression in the kidney and parathyroid gland
is reduced. This may cause the attachment of FGF-23 to FGF-
23 receptors in other tissue leading to development of cardio
toxicity in CRF. In the second mechanism attachment of FGF-
23 to speciﬁc cardiac FGF receptors like FGF receptor-4 even
in the absence of klotho may contribute to development of
LVH22. In a study, besides inducing LVH, elevated FGF-23 has
been shown to adversely affect the mechanics of left ventricle
in HD patients28. The data of an experimental study showed
that FGF23 may have additional effects on the heart, in addi-
tion to hypertrophy, speciﬁcally related to calcium handling
and cardiac contractility29. In a population study, non-sudden
cardiac death is found to be associated with high FGF-2330.
Recently in the meta-analysis of prospective cohort studies,
a relationship between FGF-23 and all-cause mortality and
cardiovascular events was observed31. However, additional
studies are required to determine FGF-23 receptors that medi-
ate the cardiac effects of FGF-23.
Nevertheless, the presence of cardiac hypertrophy and vas-
cular calciﬁcation is interesting inpatientswithmoderateCKD
(stages III–IV). These patients do not have hemodynamic and
inﬂammatory stress associated with chronic dialysis treat-
ment and hyperphosphatemia is not obvious but FGF-23 levels
are already increased32. This observation suggests that FGF-23
and phosphate might promote distinct mechanisms of car-
diovascular toxicity. Indeed, animal models implicate high
serum phosphate as a mechanism of vascular calciﬁcation
and endothelial dysfunction, whereas high levels of FGF-23
are implicated in left ventricular hypertrophy33. FGF-23 may
increase CVD by decreasing the serum 1-25(OH)2 vitamin D
levels. In this regard the data obtained from HD supports the
survival beneﬁt of active vitamin D therapy34. On the other
hand the idea that FGF-23 has a direct toxic effect on CV sys-
tem can only be excluded by prospective trials showing the
normalization of FGF-23 by active vitamin D therapy.
Anemia is one of the common complications of CKD and
is associated with mortality and cardiovascular events, even
after accounting for CKD stage and other cardiovascular risk
factors35. In addition, the effect of anemia on CV disease and
LVH is well known in CKD patients9. Interestingly in this study
signiﬁcant negative correlation was determined between FGF-
23 and hemoglobin concentration and TSAT. Furthermore in
high FGF-23 group although statistically insigniﬁcant, num-
ber of patients having hemoglobin levels lower than 10g/dl
and using erythropoietin was higher. Also in regression anal-
ysis the negative relation between FGF-23 and hemoglobin is
persisted. A study, in HD patients no correlation was detected
between hemoglobin and FGF-2336. However, in HD patients
especially in patients with ischemic heart disease and heart
failure, higher hemoglobin levels have been shown to increase
the risk of mortality and morbidity37. For these reasons, the
effect of relationship between FGF-23 and anemia on the CV
system must be determined in further studies.
A relation between iron and FGF-23 metabolism is men-
tioned in a few studies. In human and animalswith autosomal
dominant hypophosphatemic rickets (ADHR) a correlation
between elevated FGF-23 with low serum iron was detected.
However, in healthy controls, low serum iron was correlated
with elevated c-terminal FGF-23 (cFGF-23), but not with iFGF-
23. This may suggest that cleavage maintains homeostasis
despite increased FGF-23 expression10,38. Similar results were
also obtained in patients with X-linked hypophosphatemia39.
In studies in children and the elderly population also a
relationship between FGF-23 and low serum iron level was
detected40,41. In studies, it is emphasized that iron deﬁciency
is an important stimulator of FGF-23 transcription. At the
same time, iron is thought to be the cofactor of enzymes tak-
ing part in the degradation of intact FGF-23 and thought to
have a role in the excretion of degraded FGF-23 parts10,38–41.
In another study, the CKD patients with iron deﬁciency
and autosomal dominant rickets showed similar molecular
pathophysiology and osteocyte dysfunction is suggested to
be increased by iFGF-23 level42. Despite major advances in
understanding FGF23 biology, fundamental aspects of FGF23
regulation in healthy subjects and in CKD remain mostly
unknown.
In many human and animal studies effect of different
iron preparations on FGF-23 and phosphate levels is inves-
tigated. Iron polymaltose infusions were demonstrated to
raise i-FGF23 concentrations causing hypophosphatemia and
osteomalacia in individuals with normal renal function43. In
a study intravenous (IV) ferric carboxymaltose (FCM) and iron
dextran (ID) were used. C-terminal FGF-23 was decreased after
the use of both drugs. But only in FCM group iFGF-23 increased
temporarily and serum phosphorous is decreased44. Besides
this in HD patients PTH suppression and rise in iFGF-23 level
after IV low molecular weight ID treatment was observed45.
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In another study in HD patients iFGF-23 level was found to
be negatively associated to intravenous iron sucrose use inde-
pendently from serum ferritin and iron levels. But in this study
there was no data about the association of hemoglobin and
iFGF-2346. Researchers think some carbohydrate components
in iron preparations to inhibit FGF-23 degradation in osteo-
cytes to cause a transient raise in iFGF-2344–46. In another study
iron isomaltose and FCM given intraperitoneally were shown
to have no effect on plasma iFGF23 levels both in normal and
uremic rats47. In a recent double blinded, placebo-controlled,
randomized trial, rise in hemoglobin levels and decline in
serum phosphate and iFGF-23 levels were detected after the
use of oral ferric citrate for 12weeks48. Also in an experimental
study, FGF-23 is expressed to have negative effect on erythro-
cyte production anddifferentiation49. In our study group, none
of the patients were under intravenous iron treatment. Lower
than the half of the patients was using oral iron drugs and
the percentage was similar in both groups. Negative corre-
lation was detected between iFGF-23 and hemoglobin levels
independent from serum ferritin, TSAT and oral iron usage in
patients. The results of our studies and other studies suggest
an association between disease and FGF-23 metabolism.
Clinical study number in which FGF-23 concentrations are
measured is increasing. But studies in which iFGF-23 (kainos;
immutopics) and cFGF-23 (immutopics) measurements are
compared are inadequate. In a study intra-assay variation was
found to be good in all three assays but in terms of inter-
assay and linearity, kainos iFGF-23 and cFGF-23 assays were
found to be better50. In another study strong positive correla-
tion was determined between iFGF assays and cFGF assay in
the HD patients51. In a study an important diurnal variation is
detected in iFGF-23 so the use of cFGF-23 is thought to be more
useful in clinical practice52. Also both immunotrophic assays
are thought to be affected from ferritin levels but this situation
does not occur in kainos iFGF-23 assay53. As a result of these
data we think the use of both iFGF-23 assay and cFGF-23 assay
together may be suitable.
There are some limitations in this cross sectional study.
Due to the design of the study left ventricular function and
geometrywas assessed by echocardiography and changes that
have occurred over time are shown. But iFGF-23 levels were
measured once and possibility of change in serum iFGF-23
level during the time period could not be known. However,
only iFGF-23 levels were measured. Otherwise, this is a single-
centered study, the number of patients and race diversity is
limited. Due to the cross-sectional design of the study we can
only talk about a relationship based on the data but not a
causal relationship so interpretations should be made care-
fully.
In conclusion, data presented in this study and recent pub-
lications about the relationship between CV risk factors and
anemia with FGF-23, suggests a wider role of this marker
in normal biological systems. Well-designed prospective ran-
domized trials are needed to investigate its exact role in the
pathogenesis of CVD and anemia in CKD.
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